Fulcrum Therapeutics
FULC
110 hedge funds and large institutions have $366M invested in Fulcrum Therapeutics in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 47 increasing their positions, 25 reducing their positions, and 17 closing their positions.
1,008% more call options, than puts
Call options by funds: $4.21M | Put options by funds: $380K
88% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 25
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
5% more funds holding
Funds holding: 105 → 110 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.85% less ownership
Funds ownership: 103.13% → 97.28% (-5.8%)
13% less capital invested
Capital invested by funds: $422M → $366M (-$56.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16.3M |
| 2 |
RI
RTW Investments
New York
|
+$6.57M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$4.87M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.26M |
| 5 |
BlackRock
New York
|
+$3.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.8M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$13M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.1M |
| 4 |
CAC
Cowen and Company
New York
|
-$6.44M |
| 5 |
VA
VR Adviser
New York
|
-$4.91M |
FULC Hedge Fund Activity: Q4 2022 in Review
110 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2022, worth a combined $366M — down 13% from $422M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new FULC positions and 17 closed out — a net gain of 5 holders — while 47 added to existing stakes and 25 trimmed.
The largest buyer was RA Capital Management, adding an estimated $16.3M. The largest seller was Fidelity Investments, cutting an estimated $16.8M.
- 110 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2022, up from 105 in Q3 2022.
- Funds reported $366M of Fulcrum Therapeutics stock for Q4 2022, down 13% quarter-over-quarter.
- 22 funds opened new Fulcrum Therapeutics positions in Q4 2022 and 17 closed out, a net change of +5 holders.
- The largest Fulcrum Therapeutics buyer in Q4 2022 was RA Capital Management, an estimated $16.3M added.
- The largest Fulcrum Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $16.8M sold.
Based on aggregated 13F filings for Q4 2022.